Patients, physicians, pharmacists, or other healthcare professionals with additional questions about OXBRYTA should contact Pfizer Medical Information 1-800-438-1985.

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Pfizer Inc. (NYSE: PFE) announced ... Patients, physicians, pharmacists, or other healthcare professionals with additional questions about OXBRYTA should contact Pfizer Medical Information 1-800 ...

Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets. Decision comes two years after acquiring the drug’s parent company, Global Blood Therapeutic, in a $5.4 billion deal. By .

In the second quarter of 2024, Oxbryta generated sales of $92 million, up 20% year-over-year.Pfizer added Oxbryta to its portfolio via its $5.4 billion buyout of Global Blood Therapeutics in 2022. ...

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.

The benefit of Oxbryta “no longer outweighs the risk in the approved sickle-cell patient population,” Pfizer said. Photo: Getty Images ...

(Reuters) - Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts ...

Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease ...

Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall.

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® for the treatment of sickle cell disease at this time, in all markets where it is approved.